The Delivery Challenge in Neurodegenerative Disorders: The Nanoparticles Role in Alzheimer’s Disease Therapeutics and Diagnostics
Alzheimer’s disease (AD) is one of the main causes of disability and dependency among elderly people. AD is a neurodegenerative disorder characterized by a progressive and irreversible cognitive impairment, whose etiology is unclear because of the complex molecular mechanisms involved in i...
Main Authors: | Cristina de la Torre, Valentín Ceña |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-10-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4923/10/4/190 |
Similar Items
-
Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer’s Disease
by: Laura Del Amo, et al.
Published: (2021-05-01) -
Rhynchophylline Loaded-mPEG-PLGA Nanoparticles Coated with Tween-80 for Preliminary Study in Alzheimer’s Disease
by: Xu R, et al.
Published: (2020-02-01) -
Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours
by: Ferraris C, et al.
Published: (2020-04-01) -
Advancements in the Blood–Brain Barrier Penetrating Nanoplatforms for Brain Related Disease Diagnostics and Therapeutic Applications
by: Suresh Thangudu, et al.
Published: (2020-12-01) -
Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer’s Disease
by: Eniko Manek, et al.
Published: (2020-10-01)